Evaluating the use of Uromune(®) autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain. Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens. This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus from January 2018 to August 2022, assessed the association between Uromune administration and changes in recurrent UTIs. Patients received personalized autovaccines administered as two sublingual puffs daily for three months. Clinical
Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects. To prospectively analyze the efficacy of uromune® in the prevention of uncomplicated recurrent urinary tract infections at 3 and 6 months, and according to gender and menopause. From September 2011 to December 2017 uromune® of treatment. The results with positive urine culture were registered at 3 and 6 months after the end of the treatment according to gender and also in the menopausal group with respect to pre-menopausal women. Mean age was 73.5 years. 82.7% were women and 94.3% menopausal. The number of episodes of urinary tract infections in the 12 months prior to uromune® were 3 in 37.2%, 4 in 28.1%, 5 in 19.5%, 6 in 9.6
First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. To determine the effectiveness of Uromune in preventing recurrent urinary tract infections (UTIs) in women. A total of 77 women with microbiology-proven recurrent UTIs were given Uromune sublingual vaccine for a period of 3 months. Time to first UTI recurrence of recurrences occurred in postmenopausal women. One patient had to stop treatment because of an adverse event (rash over face and neck). This prospective study suggests that Uromune is safe and effective at preventing UTIs in women. Further research is required in larger groups of patients for longer treatment times. An international double-blind randomized control trial comparing Uromune with placebo
. These follow-up consultations will primarily occur via telephone review, however, there will be flexibility for in-person reviews for participants who find telephone consultation prohibitively difficult. This is a multicentre, double-blinded, randomised control trial, the first in Australia to assess the safety and efficacy of MV140 Uromune vaccine in prevention of recurrent UTIs. Results have been
Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI) An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance. UROMUNE® is a mucosal immunotherapy indicated for the prevention of urinary tract infections caused by different pathogens. It works by stimulating the immune system, thus increasing the resistance against recurrent infections. The active substances are 4 inactivated and selected bacterial strains:Klebsiella pneumoniae 25%Escherichia coli 25%Enterococcus faecalis 25
Uromune in Treating Recurrent Urinary Tract Infections in Women To determine the effectiveness and safety of the vaccine Uromune in Canadian women with recurrent urinary tract infection. The proposal is for a real life clinical practice study in which female participants with a predefined history of recurrent UTIs in the previous year will be treated with 3 months of oral vaccine with a further 9
with recurrent urinary tract infections with the bacterial vaccine Uromune(®). BJU Int. 2018 Feb;121(2):289-292. doi: 10.1111/bju.14067. Epub 2017 Nov 23. Responsible Party: Inmunotek S.L. ClinicalTrials.gov Identifier: NCT02543827 Other Study ID Numbers: MV140-SLG-003